Catalyst Pharmaceuticals (NASDAQ:CPRX) Price Target Raised to $36.00 at Truist Financial

Catalyst Pharmaceuticals (NASDAQ:CPRX - Free Report) had its target price upped by Truist Financial from $30.00 to $36.00 in a research report sent to investors on Monday,Benzinga reports. The brokerage currently has a buy rating on the biopharmaceutical company's stock.

Several other research analysts also recently weighed in on the company. StockNews.com upgraded Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Friday, August 9th. HC Wainwright restated a "buy" rating and set a $30.00 price objective on shares of Catalyst Pharmaceuticals in a report on Friday. Finally, Citigroup upped their price objective on Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the stock a "buy" rating in a report on Friday, August 9th. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $30.50.

Catalyst Pharmaceuticals Stock Performance

CPRX stock traded down $0.48 on Monday, reaching $23.45. The company had a trading volume of 1,929,695 shares, compared to its average volume of 1,195,088. Catalyst Pharmaceuticals has a 1 year low of $12.43 and a 1 year high of $24.27. The company's fifty day moving average is $20.81 and its 200 day moving average is $18.17. The company has a market cap of $2.80 billion, a P/E ratio of 19.87, a PEG ratio of 3.82 and a beta of 0.75.

Insider Buying and Selling

In related news, insider Steve Miller sold 150,000 shares of the firm's stock in a transaction that occurred on Tuesday, August 20th. The shares were sold at an average price of $20.35, for a total value of $3,052,500.00. Following the completion of the transaction, the insider now owns 675,124 shares of the company's stock, valued at approximately $13,738,773.40. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other Catalyst Pharmaceuticals news, insider Steve Miller sold 150,000 shares of Catalyst Pharmaceuticals stock in a transaction on Tuesday, August 20th. The shares were sold at an average price of $20.35, for a total transaction of $3,052,500.00. Following the completion of the sale, the insider now owns 675,124 shares of the company's stock, valued at $13,738,773.40. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director David S. Tierney sold 15,000 shares of Catalyst Pharmaceuticals stock in a transaction on Wednesday, August 21st. The shares were sold at an average price of $20.10, for a total transaction of $301,500.00. Following the sale, the director now directly owns 348,874 shares of the company's stock, valued at $7,012,367.40. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 11.00% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of CPRX. Pacer Advisors Inc. grew its position in Catalyst Pharmaceuticals by 130,918.8% in the 2nd quarter. Pacer Advisors Inc. now owns 2,967,575 shares of the biopharmaceutical company's stock worth $45,968,000 after purchasing an additional 2,965,310 shares during the last quarter. Janus Henderson Group PLC boosted its position in shares of Catalyst Pharmaceuticals by 139.5% during the 1st quarter. Janus Henderson Group PLC now owns 2,726,388 shares of the biopharmaceutical company's stock valued at $43,445,000 after acquiring an additional 1,587,794 shares in the last quarter. Vanguard Group Inc. boosted its position in Catalyst Pharmaceuticals by 12.1% in the first quarter. Vanguard Group Inc. now owns 7,980,661 shares of the biopharmaceutical company's stock valued at $127,212,000 after buying an additional 860,244 shares in the last quarter. Kennedy Capital Management LLC boosted its position in Catalyst Pharmaceuticals by 101.1% in the first quarter. Kennedy Capital Management LLC now owns 1,061,704 shares of the biopharmaceutical company's stock valued at $16,924,000 after buying an additional 533,802 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its position in Catalyst Pharmaceuticals by 15.2% in the second quarter. Renaissance Technologies LLC now owns 2,175,727 shares of the biopharmaceutical company's stock valued at $33,702,000 after buying an additional 287,300 shares in the last quarter. Institutional investors own 79.22% of the company's stock.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.